Spruce Biosciences to Present Long-Term Data on Sanfilippo Syndrome Treatment at WORLDSymposium — Spruce Biosciences, Inc.

Event summary

Spruce Biosciences will present data on long-term administration of tralesinidase alfa (TA-ERT) for Sanfilippo syndrome type B (MPS IIIB) at WORLDSymposium 2026.
Presentations include a platform session on February 5, 2026, detailing durable reduction of heparan sulfate and stabilization of cognitive function.
A second poster presentation will compare outcomes of treated vs. untreated siblings with MPS IIIB.
Presenters include Nicole Muschol, M.D., from ICLD, and Irene J. Chang, M.D., from UC San Francisco.

The big picture

Spruce Biosciences' presentations at WORLDSymposium 2026 come at a critical juncture for rare disease therapies, particularly in neurological disorders with limited treatment options. The focus on long-term efficacy data and comparative outcomes highlights the growing emphasis on demonstrating durable clinical benefits in orphan disease indications. The company's progress with TA-ERT could position it as a key player in the enzyme replacement therapy space, pending successful regulatory and commercial execution.

What we're watching

Clinical Efficacy: Whether long-term data on TA-ERT will demonstrate sustained cognitive benefits in MPS IIIB patients.
Regulatory Pathway: The pace at which positive data could accelerate Spruce Biosciences' regulatory filings.
Competitive Positioning: How comparative outcomes between treated and untreated siblings may influence market perception of TA-ERT.